Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazonePEULER, Jacob D; WARFIELD, R. K. N; PHELPS, Laura E et al.Metabolism, clinical and experimental. 2004, Vol 53, Num 2, pp 147-152, issn 0026-0495, 6 p.Article

Sequence variation in PPARG may underlie differential response to troglitazoneWOLFORD, Johanna K; YEATTS, Kimberly A; DHANJAL, Sharanjeet K et al.Diabetes (New York, NY). 2005, Vol 54, Num 11, pp 3319-3325, issn 0012-1797, 7 p.Article

Troglitazone : the lesson that nobody learned?GALE, Edwin A. M.Diabetologia (Berlin). 2006, Vol 49, Num 1, pp 1-6, issn 0012-186X, 6 p.Article

Troglitazone and liver injury: In search of answersCHOJKIER, Mario.Hepatology (Baltimore, Md.). 2005, Vol 41, Num 2, pp 237-246, issn 0270-9139, 10 p.Article

Liver enzyme monitoring in patients treated with troglitazoneGRAHAM, David J; DRINKARD, Carol R; SHATIN, Deborah et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 7, pp 831-833, issn 0098-7484Article

Ontology-based knowledge management of troglitazone-induced hepatotoxicityHUG, Hubert; DANNECKER, Robert; SCHINDLER, Richard et al.Drug discovery today. 2004, Vol 9, Num 22, pp 948-954, issn 1359-6446, 7 p.Article

Effects of troglitazone in young first-degree Relatives of patients with type 2 diabetesLEVIN, Klaus; HOTHER-NIELSEN, Ole; HENRIKSEN, Jan Erik et al.Diabetes care. 2004, Vol 27, Num 1, pp 148-154, issn 0149-5992, 7 p.Article

Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemicsKUBOTA, Kiyoshi; KAWABE, Eri; HINOTSU, Shiro et al.European journal of clinical pharmacology. 2001, Vol 56, Num 11, pp 831-838, issn 0031-6970Article

Mechanism of troglitazone action in type 2 diabetesPETERSEN, K. F; KRSSAK, M; INZUCCHI, S et al.Diabetes (New York, NY). 2000, Vol 49, Num 5, pp 827-831, issn 0012-1797Article

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γMINGHAN WANG; WISE, S. C; LEFF, T et al.Diabetes (New York, NY). 1999, Vol 48, Num 2, pp 254-260, issn 0012-1797Article

Troglitazone, a Ligand of Peroxisome Proliferator-Activated Receptor-γ, Stabilizes NUCB2 (Nesfatin) mRNA by Activating the ERK1/2 Pathway: Isolation and Characterization of the Human NUCB2 GeneYAMADA, Masanobu; HORIGUCHI, Kazuhiko; MORI, Masatomo et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 6, pp 2494-2503, issn 0013-7227, 10 p.Article

Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involvedKAN HE; TALAAT, Rasmy E; POOL, William F et al.Drug metabolism and disposition. 2004, Vol 32, Num 6, pp 639-646, issn 0090-9556, 8 p.Article

Thiazolidinediones : Données cliniques et perspectives = Thiazolidinediones : Clinical data and perspectivesBLICKLE, J. F.Diabetes & metabolism. 2001, Vol 27, Num 2, pp 279-285, issn 1262-3636, 2Article

Effect of troglitazone on urinary excretion of 6β-hydroxycortisolKOUP, J. R; ANDERSON, G. D; LOI, C.-M et al.Journal of clinical pharmacology. 1998, Vol 38, Num 9, pp 815-818, issn 0091-2700Conference Paper

Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazoneROTHWELL, Charles; MCGUIRE, Edward J; ALTROGGE, Douglas M et al.Journal of toxicological sciences. 2002, Vol 27, Num 1, pp 35-47, issn 0388-1350Article

Troglitazone and liver function abnormalities: Lessons from a prescription Event monitoring study and spontaneous reportingBISWAS, Pipasha; WILTON, Lynda V; SHAKIR, Saad A et al.Drug safety. 2001, Vol 24, Num 2, pp 149-154, issn 0114-5916Article

Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitisJAMES LENHARD, M; FUNK, William B.Diabetes care. 2001, Vol 24, Num 1, pp 168-169, issn 0149-5992Article

Evaluation of solid state form of troglitazone by solid state NMR spectroscopySUZUKI, Nobuyuki; KAWASAKI, Takao.Journal of pharmaceutical and biomedical analysis. 2005, Vol 37, Num 1, pp 177-181, issn 0731-7085, 5 p.Article

Prevention of type 2 diabetes with troglitazone in the diabetes prevention programDiabetes (New York, NY). 2005, Vol 54, Num 4, pp 1150-1156, issn 0012-1797, 7 p.Article

Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cellsKONRAD, D; RUDICH, A; BILAN, P. J et al.Diabetologia (Berlin). 2005, Vol 48, Num 5, pp 954-966, issn 0012-186X, 13 p.Article

Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. CommentaryWATANABE, Kouki; KOMATSU, Jiroh; KURATA, Makoto et al.Journal of hypertension. 2004, Vol 22, Num 9, pp 1671-1672, issn 0263-6352, 10 p.Article

Troglitazone antagonizes metabolic effects of glucocorticoids in humans: Effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptinWILLI, Steven M; KENNEDY, Adele; WALLACE, Penny et al.Diabetes (New York, NY). 2002, Vol 51, Num 10, pp 2895-2902, issn 0012-1797, 8 p.Article

Effects of troglitazone in hispanic patients with type 2 diabetes mellitus : Trials in special populationsMAVANDADI, A; GONG, W. C.Current therapeutic research. 1999, Vol 60, Num 9, pp 494-501, issn 0011-393XArticle

A miracle of salamization : Positive divided by two equals negativeGÜRLEK, A; ÖZDEMIR, O.Diabetic medicine. 1997, Vol 14, Num 4, pp 334-335, issn 0742-3071Article

Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities : Pharmaceutical Design of Novel Anticancer Agents: A Lesson from NatureQIU ZHANG; HONGYU ZHOU; SHUMEI ZHAI et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 16, pp 1826-1842, issn 1381-6128, 17 p.Article